Skip to main content
Erschienen in: Clinical & Experimental Metastasis 1/2007

01.03.2007 | Research Paper

Clinical and radiological evaluation of patients with lytic, mixed and sclerotic bone metastases from solid tumors: is there a correlation between clinical status of patients and type of bone metastases?

verfasst von: Vassilios Vassiliou, Christine Kalogeropoulou, Theodoros Petsas, Michael Leotsinidis, Dimitrios Kardamakis

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose To investigate the association between the clinical status of patients with metastatic bone disease and the type of bone metastases. Patients and methods 80 patients with skeletal metastases underwent both clinical and radiological assessments. Bone lesions were evaluated with computed tomography (CT), and patients were separated into three groups: lytic, mixed, sclerotic. Bone density of each lesion was measured in Hounsfield units (HU). Results Patients with osteolytic lesions had the highest mean pain score with 8.1 ± 2.2 points, the least mean scores for quality of life (QoL) and performance status (PS) with 31.4 ± 14.6 and 58.6 ± 9.7 points respectively, the highest percentage and mean opioid consumption (100% and 220.9 mg of oral daily morphine equivalent respectively), and the least mean bone density (116.3 ± 40.4 HU). On the contrary, the group with sclerotic metastases had the least mean pain score with 4.6 ± 1.3 points, the highest mean scores of QoL and PS (61.1 ± 15.5 and 66.6 ± 10 points respectively), the least percentage and mean opioid requirement (55.5% and 170.6 mg respectively), and the highest mean bone density (444 ± 86.6 HU). The differences between the three groups were statistically significant for all parameters evaluated, apart from performance status between the sclerotic and mixed groups. The correlation coefficients were statistically significant between all parameters investigated. Bone density had a strong negative correlation with pain. Conclusion Our results show a clear correlation between the type of bone metastases and the clinical status of patients. Patients with excessive bone resorption suffer the most, and may be given priority in treatment. CT proved to be a practical and efficient method to investigate and classify metastatic bone lesions.
Literatur
1.
Zurück zum Zitat Brown HK, Healy JH (2001) Metastatic cancer in bone. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer–principles and practice of oncology, 6 edn. Lippincott Williams and Wilkins, Philadelphia, pp 2713–2729 Brown HK, Healy JH (2001) Metastatic cancer in bone. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer–principles and practice of oncology, 6 edn. Lippincott Williams and Wilkins, Philadelphia, pp 2713–2729
2.
Zurück zum Zitat Body JJ (1992) Metastatic bone disease: clinical and therapeutic aspects. Bone 13:557–562CrossRef Body JJ (1992) Metastatic bone disease: clinical and therapeutic aspects. Bone 13:557–562CrossRef
3.
Zurück zum Zitat Mauskop A, Foley KM (1998) Control of pain. In: Harrigton KD (ed) Orthopedic management of metastatic bone disease. CV Mosby, St Lewis, pp 121–137 Mauskop A, Foley KM (1998) Control of pain. In: Harrigton KD (ed) Orthopedic management of metastatic bone disease. CV Mosby, St Lewis, pp 121–137
4.
Zurück zum Zitat Pecherstorfer M, Vesely M (2000) Diagnosis and monitoring of bone metastases: clinical means. In: Body JJ (ed) Tumor bone disease and osteoporosis in cancer patients. Marcel Dekker, Inc., New York, pp 97–129 Pecherstorfer M, Vesely M (2000) Diagnosis and monitoring of bone metastases: clinical means. In: Body JJ (ed) Tumor bone disease and osteoporosis in cancer patients. Marcel Dekker, Inc., New York, pp 97–129
5.
Zurück zum Zitat Vinholes JJ, Purohit OP, Abbey ME et al (1997) Relationships between biochemical and symptomatic response in a double–blind randomized trial of pamidronate for metastatic bone disease. Ann Oncol 8:1243–1250PubMedCrossRef Vinholes JJ, Purohit OP, Abbey ME et al (1997) Relationships between biochemical and symptomatic response in a double–blind randomized trial of pamidronate for metastatic bone disease. Ann Oncol 8:1243–1250PubMedCrossRef
6.
Zurück zum Zitat Peh WCG, Muttarak M (2003) Clinics in diagnostic Imaging (82). Singapore Med J 44(2):101–105PubMed Peh WCG, Muttarak M (2003) Clinics in diagnostic Imaging (82). Singapore Med J 44(2):101–105PubMed
7.
Zurück zum Zitat Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176PubMedCrossRef Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176PubMedCrossRef
8.
Zurück zum Zitat Maisano R, Pergolizzi S, Cascinu S (2001) Novel therapeutic approaches to cancer patients with bone metastasis. Crit rev Oncol/Hematol 40:239–250CrossRef Maisano R, Pergolizzi S, Cascinu S (2001) Novel therapeutic approaches to cancer patients with bone metastasis. Crit rev Oncol/Hematol 40:239–250CrossRef
9.
Zurück zum Zitat Iddon J, Byrne G, Bundred NJ (1999) Bone metastasis in breast cancer: the role of parathyroid hormone related protein. Surg oncol 8:13–25PubMedCrossRef Iddon J, Byrne G, Bundred NJ (1999) Bone metastasis in breast cancer: the role of parathyroid hormone related protein. Surg oncol 8:13–25PubMedCrossRef
10.
Zurück zum Zitat Bonadonna G, Rossi A, Valagussa P et al (1997) The CMF program for operable breast cancer with positive axillary nodes. Cancer 39:2904–2915CrossRef Bonadonna G, Rossi A, Valagussa P et al (1997) The CMF program for operable breast cancer with positive axillary nodes. Cancer 39:2904–2915CrossRef
11.
Zurück zum Zitat Chow E, Holden L, Rubenstein J et al (2004) Computed Tomography (CT) evaluation of breast cancer patients with osteolytic bone metastases undergoing palliative radiotherapy–a feasibility study. Radiother Oncol 70:291–294PubMedCrossRef Chow E, Holden L, Rubenstein J et al (2004) Computed Tomography (CT) evaluation of breast cancer patients with osteolytic bone metastases undergoing palliative radiotherapy–a feasibility study. Radiother Oncol 70:291–294PubMedCrossRef
12.
Zurück zum Zitat Karnofsky DA, Abelmann WH, Craver LF et al (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1:634CrossRef Karnofsky DA, Abelmann WH, Craver LF et al (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1:634CrossRef
13.
Zurück zum Zitat Aaronson NK, Ahmedzai S, Bergman B et al (1993) For the European organization for research and treatment of cancer QLQ-C30: a quality of life instrument for use in international trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef Aaronson NK, Ahmedzai S, Bergman B et al (1993) For the European organization for research and treatment of cancer QLQ-C30: a quality of life instrument for use in international trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef
14.
Zurück zum Zitat Storto G, Klain M, Paone G et al (2006) Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 39:35–41PubMedCrossRef Storto G, Klain M, Paone G et al (2006) Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 39:35–41PubMedCrossRef
15.
Zurück zum Zitat Vassiliou V, Kalogeropoulou C, Christopoulos C et al. (2007) Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. Int J Radiat Oncol Biol Phys 67(1): 264–272PubMed Vassiliou V, Kalogeropoulou C, Christopoulos C et al. (2007) Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. Int J Radiat Oncol Biol Phys 67(1): 264–272PubMed
16.
Zurück zum Zitat Chow E, Ling A, Davis L et al (2005) Pain flare following external beam radiotherapy and meaningful change in pain scores in the treatment of bone metastases. Radiotherapy Oncol 75:64–69CrossRef Chow E, Ling A, Davis L et al (2005) Pain flare following external beam radiotherapy and meaningful change in pain scores in the treatment of bone metastases. Radiotherapy Oncol 75:64–69CrossRef
17.
Zurück zum Zitat Umatsu T, Yuen S, Yukisawa S et al (2005) Comparison of FDGPET and SPECT for detection of bone metastases in breast cancer. AJR 184:1266–1273 Umatsu T, Yuen S, Yukisawa S et al (2005) Comparison of FDGPET and SPECT for detection of bone metastases in breast cancer. AJR 184:1266–1273
18.
Zurück zum Zitat Southard TE, Southard KA (1996) Detection of simulated osteoporosis in maxillae using radiographic texture analysis. IEEE Trans Biom Eng 43:123–132CrossRef Southard TE, Southard KA (1996) Detection of simulated osteoporosis in maxillae using radiographic texture analysis. IEEE Trans Biom Eng 43:123–132CrossRef
Metadaten
Titel
Clinical and radiological evaluation of patients with lytic, mixed and sclerotic bone metastases from solid tumors: is there a correlation between clinical status of patients and type of bone metastases?
verfasst von
Vassilios Vassiliou
Christine Kalogeropoulou
Theodoros Petsas
Michael Leotsinidis
Dimitrios Kardamakis
Publikationsdatum
01.03.2007
Verlag
Kluwer Academic Publishers
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 1/2007
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-007-9056-z

Weitere Artikel der Ausgabe 1/2007

Clinical & Experimental Metastasis 1/2007 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.